Biotechnology firm Biocon today said it has received Establishment Inspection Report (EIR) from the US health regulator on closure of inspection of its sterile drug product manufacturing facility in Bengaluru.
“The company confirms that Biocon has received an EIR from the US Food and Drug Administration (USFDA) for its sterile drug product manufacturing facility in Bangalore, following the USFDA pre-approval/inspection of this facility in April/May 2018,” a Biocon spokesperson said in a BSE filing.
It said the EIR notified that the “inspection stands closed“.
“Biocon is committed to global standards of quality and compliance,” the statement said.
The USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.